Vanguard Group Inc. Has $67.06 Million Holdings in Collegium Pharmaceutical, Inc. $COLL

Vanguard Group Inc. cut its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 1.6% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,246,568 shares of the specialty pharmaceutical company's stock after selling 36,098 shares during the period. Vanguard Group Inc. owned approximately 6.99% of Collegium Pharmaceutical worth $67,060,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Collegium Pharmaceutical by 1.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,221 shares of the specialty pharmaceutical company's stock valued at $522,000 after buying an additional 339 shares during the last quarter. SummerHaven Investment Management LLC raised its holdings in Collegium Pharmaceutical by 1.9% in the 1st quarter. SummerHaven Investment Management LLC now owns 24,354 shares of the specialty pharmaceutical company's stock valued at $727,000 after buying an additional 448 shares during the last quarter. Farther Finance Advisors LLC raised its holdings in Collegium Pharmaceutical by 4.5% in the 1st quarter. Farther Finance Advisors LLC now owns 11,091 shares of the specialty pharmaceutical company's stock valued at $326,000 after buying an additional 477 shares during the last quarter. Virtus Fund Advisers LLC raised its holdings in Collegium Pharmaceutical by 30.5% in the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company's stock valued at $69,000 after buying an additional 565 shares during the last quarter. Finally, SG Americas Securities LLC raised its holdings in Collegium Pharmaceutical by 4.2% in the 1st quarter. SG Americas Securities LLC now owns 14,277 shares of the specialty pharmaceutical company's stock valued at $426,000 after buying an additional 578 shares during the last quarter.

Collegium Pharmaceutical Stock Down 1.0%

Collegium Pharmaceutical stock opened at $39.11 on Monday. The company has a debt-to-equity ratio of 3.27, a quick ratio of 1.10 and a current ratio of 1.18. Collegium Pharmaceutical, Inc. has a 52-week low of $23.23 and a 52-week high of $42.29. The firm has a 50 day moving average price of $32.42 and a two-hundred day moving average price of $30.04. The firm has a market cap of $1.23 billion, a price-to-earnings ratio of 37.61 and a beta of 0.68.

Collegium Pharmaceutical declared that its Board of Directors has authorized a share buyback program on Monday, July 7th that authorizes the company to repurchase $150.00 million in outstanding shares. This repurchase authorization authorizes the specialty pharmaceutical company to purchase up to 15.4% of its shares through open market purchases. Shares repurchase programs are often a sign that the company's board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on COLL. HC Wainwright upgraded shares of Collegium Pharmaceutical to a "strong-buy" rating and set a $44.00 price objective for the company in a report on Monday, August 11th. Wall Street Zen upgraded shares of Collegium Pharmaceutical from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 9th. Finally, Piper Sandler reiterated a "neutral" rating and issued a $37.00 price objective (up previously from $36.00) on shares of Collegium Pharmaceutical in a report on Friday, May 9th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $42.33.

Insider Activity

In other news, Director John Gordon Freund sold 11,659 shares of Collegium Pharmaceutical stock in a transaction on Friday, August 8th. The shares were sold at an average price of $34.36, for a total value of $400,603.24. Following the completion of the sale, the director owned 23,129 shares in the company, valued at $794,712.44. The trade was a 33.51% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Gino Santini sold 5,405 shares of the business's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $37.19, for a total transaction of $201,011.95. Following the sale, the director owned 95,042 shares of the company's stock, valued at $3,534,611.98. This trade represents a 5.38% decrease in their position. The disclosure for this sale can be found here. Insiders sold 44,915 shares of company stock worth $1,614,825 in the last quarter. 2.51% of the stock is owned by corporate insiders.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.